Patents by Inventor Neil H. Bander
Neil H. Bander has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20090238755Abstract: Use of antibodies or binding portions thereof, probes, ligands, or other biological agents which either recognize an extracellular domain of prostate specific membrane antigen (PSMA) or bind to and are internalized with PSMA. These biological agents can be labeled and used for detection of cancerous tissues, particularly cancerous tissues proximate to or containing vascular endothelial cells, which express an extracellular domain of PSMA. The labeled biological agents can also be used to detect normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof. They also can be used alone or bound to a substance effective to ablate or kill such cells as a therapy for prostate or other cancers. Also disclosed are four hybridoma cells lines, each of which produces a monoclonal antibody recognizing extracellular domains of PSMA of normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof.Type: ApplicationFiled: November 13, 2007Publication date: September 24, 2009Inventor: Neil H. Bander
-
Patent number: 7514078Abstract: Modified antibodies, or antigen-binding fragments thereof, to the extracellular domain of human prostate specific membrane antigen (PSMA) are provided. The modified anti-PSMA antibodies, or antigen-binding fragments thereof, have been rendered less immunogenic compared to their unmodified counterparts to a given species, e.g., a human. Pharmaceutical compositions including the aforesaid antibodies, nucleic acids, recombinant expression vectors and host cells for making such antibodies and fragments are also disclosed. Methods of using the antibodies of the invention to detect human PSMA, or to ablate or kill a PSMA-expressing cell, e.g., a PSMA-expressing cancer or prostatic cell, either in vitro or in vivo, are also provided.Type: GrantFiled: May 30, 2003Date of Patent: April 7, 2009Assignee: Cornell Research Foundation, Inc.Inventors: Neil H. Bander, Francis J. Carr, Anita Hamilton
-
Patent number: 7163680Abstract: The present invention is directed to the use of antibodies or binding portions thereof, probes, ligands, or other biological agents which either recognize an extracellular domain of prostate specific membrane antigen or bind to and are internalized with prostate specific membrane antigen. These biological agents can be labeled and used for detection of cancerous tissues, particularly cancerous tissues proximate to or containing vascular endothelial cells, which express an extracellular domain of prostate specific membrane antigen. The labeled biological agents can also be used to detect normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof. They also can be used alone or bound to a substance effective to ablate or kill such cells as a therapy for prostate or other cancers.Type: GrantFiled: August 13, 2001Date of Patent: January 16, 2007Assignee: Cornell Research Foundation, Inc.Inventor: Neil H. Bander
-
Patent number: 7112412Abstract: The present invention is directed to the use of antibodies or binding portions thereof, probes, ligands, or other biological agents which either recognize an extracellular domain of prostate specific membrane antigen or bind to and are internalized with prostate specific membrane antigen. These biological agents can be labeled and used for detection of normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof. They also can be used alone or bound to a substance effective to ablate or kill such cells as a therapy for prostate cancer. Also disclosed are four hybridoma cell lines, each of which produces a monoclonal antibody recognizing extracellular domains of prostate specific membrane antigens of normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof.Type: GrantFiled: July 20, 1999Date of Patent: September 26, 2006Assignee: Cornell Research Foundation, Inc.Inventor: Neil H. Bander
-
Patent number: 6770450Abstract: The present invention is directed to the use of antibodies or binding portions thereof, probes, ligands, or other biological agents which either recognize an extracellular domain of prostate specific membrane antigen or bind to and are internalized with prostate specific membrane antigen. These biological agents can be labeled and used for detection of cancerous tissues, particularly cancerous tissues proximate to or containing vascular endothelial cells, which express an extracellular domain of prostate specific membrane antigen. The labeled biological agents can also be used to detect normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof. They also can be used alone or bound to a substance effective to ablate or kill such cells as a therapy for prostate or other cancers.Type: GrantFiled: July 20, 1999Date of Patent: August 3, 2004Assignee: Cornell Research Foundation, Inc.Inventor: Neil H. Bander
-
Patent number: 6767711Abstract: The present invention is directed to the use of antibodies or binding portions thereof or probes which recognize an antigen of normal, benign, hyperplastic, and cancerous prostate epithelial cells or portions thereof. These antibodies or binding portions thereof or probes can be labeled and used for detection of such cells. They also can be used alone or bound to a substance effective to ablate or kill such cells as a therapy for prostate cancer. Also disclosed is a hybridoma cell line which produces a monoclonal antibody recognizing antigens of normal, benign, hyperplastic, and cancerous prostate epithelial cells or portions thereof.Type: GrantFiled: August 13, 2001Date of Patent: July 27, 2004Assignee: Cornell Research Foundation, Inc.Inventor: Neil H. Bander
-
Publication number: 20040136998Abstract: Methods and compositions for treating, preventing, or diagnosing insulin-related disorders, e.g., diabetes mellitus, e.g., Type 2 diabetes, are disclosed. The methods and compositions of the invention use binding agents, e.g., antibodies, specific for the extracellular domain of human prostate specific membrane antigen (PSMA).Type: ApplicationFiled: October 17, 2003Publication date: July 15, 2004Inventor: Neil H. Bander
-
Publication number: 20040120958Abstract: Modified antibodies, or antigen-binding fragments thereof, to the extracellular domain of human prostate specific membrane antigen (PSMA) are provided. The modified anti-PSMA antibodies, or antigen-binding fragments thereof, have been rendered less immunogenic compared to their unmodified counterparts to a given species, e.g., a human. Pharmaceutical compositions including the aforesaid antibodies, nucleic acids, recombinant expression vectors and host cells for making such antibodies and fragments are also disclosed. Methods of using the antibodies of the invention to detect human PSMA, or to ablate or kill a PSMA-expressing cell, e.g., a PSMA-expressing cancer or prostatic cell, either in vitro or in vivo, are also provided.Type: ApplicationFiled: May 30, 2003Publication date: June 24, 2004Inventors: Neil H. Bander, Francis J. Carr, Anita Hamilton
-
Publication number: 20040105865Abstract: The present invention is directed to the use of antibodies or binding portions thereof or probes which recognize an antigen of normal, benign, hyperplastic, and cancerous prostate epithelial cells or portions thereof. These antibodies or binding portions thereof or probes can be labeled and used for detection of such cells. They also can be used alone or bound to a substance effective to ablate or kill such cells as a therapy for prostate cancer. Also disclosed is a hybridoma cell line which produces a monoclonal antibody recognizing antigens of normal, benign, hyperplastic, and cancerous prostate epithelial cells or portions thereof.Type: ApplicationFiled: September 25, 2003Publication date: June 3, 2004Applicant: Cornell Research Foundation Inc.,Inventor: Neil H. Bander
-
Publication number: 20040087017Abstract: The present invention relates to methods for the isolation of prostatic cancer tumor cells from a biological fluid, using a magnetic activated cell sorter (MACS).Type: ApplicationFiled: June 20, 2003Publication date: May 6, 2004Inventors: Neil H. Bander, Leonard Michael Glode, Chang In Suh
-
Patent number: 6653129Abstract: The present invention relates to methods for the isolation of prostatic cancer tumor cells from a biological fluid, using a magnetic activated cell sorter (MACS).Type: GrantFiled: September 6, 2000Date of Patent: November 25, 2003Assignee: The Regents of the University of ColoradoInventors: Neil H. Bander, Leonard Michael Glode, Chang In Suh
-
Patent number: 6649163Abstract: The present invention is directed to the use of antibodies or binding portions thereof, probes, ligands, or other biological agents which either recognize an extracellular domain of prostate specific membrane antigen or bind to and are internalized with prostate specific membrane antigen. These biological agents can be labeled and used for detection of cancerous tissues, particularly cancerous tissues proximate to or containing vascular endothelial cells, which express an extracellular domain of prostate specific membrane antigen. The labeled biological agents can also be used to detect normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof. They also can be used alone or bound to a substance effective to ablate or kill such cells as a therapy for prostate or other cancers.Type: GrantFiled: July 20, 1999Date of Patent: November 18, 2003Assignee: Cornell Research Foundation, Inc.Inventor: Neil H. Bander
-
Publication number: 20030031673Abstract: The present invention is directed to the use of antibodies or binding portions thereof, probes, ligands, or other biological agents which either recognize an extracellular domain of prostate specific membrane antigen or bind to and are internalized with prostate specific membrane antigen. These biological agents can be labeled and used for detection of cancerous tissues, particularly cancerous tissues proximate to or containing vascular endothelial cells, which express an extracellular domain of prostate specific membrane antigen. The labeled biological agents can also be used to detect normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof. They also can be used alone or bound to a substance effective to ablate or kill such cells as a therapy for prostate or other cancers.Type: ApplicationFiled: August 13, 2001Publication date: February 13, 2003Inventor: Neil H. Bander
-
Publication number: 20030003101Abstract: The present invention is directed to the use of antibodies or binding portions thereof, probes, ligands, or other biological agents which either recognize an extracellular domain of prostate specific membrane antigen or bind to and are internalized with prostate specific membrane antigen. These biological agents can be labeled and used for detection of normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof. They also can be used alone or bound to a substance effective to ablate or kill such cells as a therapy for prostate cancer. Also disclosed are four hybridoma cell lines, each of which produces a monoclonal antibody recognizing extracellular domains of prostate specific membrane antigens of normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof.Type: ApplicationFiled: August 13, 2001Publication date: January 2, 2003Applicant: Cornell Research Foundation, Inc.Inventor: Neil H. Bander
-
Patent number: 6451532Abstract: This invention provides methods of: (a) diagnosing; (b) determining the stage of; and (c) monitoring the effect of a therapeutic intervention for a renal cell carcinoma in a human subject which comprises detecting the expression of the MN gene. In one embodiment, the method is directed to detection of the renal cell carcinoma known as clear cell carcinoma. In another embodiment, the method is used as a peripheral blood assay. In another embodiment, the method is a polymerase chain reaction assay for amplifying and detecting the presence of the cDNA molecule encoding the MN protein.Type: GrantFiled: October 15, 1999Date of Patent: September 17, 2002Assignees: The Trustees of Columbia University in the City of New York, Cornell Research Foundation, Inc.Inventors: James M. McKiernan, Ihor S. Sawczuk, Ralph Buttyan, Neil H. Bander
-
Publication number: 20020015704Abstract: The present invention is directed to the use of antibodies or binding portions thereof or probes which recognize an antigen of normal, benign, hyperplastic, and cancerous prostate epithelial cells or portions thereof. These antibodies or binding portions thereof or probes can be labeled and used for detection of such cells. They also can be used alone or bound to a substance effective to ablate or kill such cells as a therapy for prostate cancer. Also disclosed is a hybridoma cell line which produces a monoclonal antibody recognizing antigens of normal, benign, hyperplastic, and cancerous prostate epithelial cells or portions thereof.Type: ApplicationFiled: August 13, 2001Publication date: February 7, 2002Applicant: Cornell Research Foundation, Inc.Inventor: Neil H. Bander
-
Patent number: 6299598Abstract: A suprapubic drainage catheter (10) for draining the bladder and maintaining the patency of the urethra of a patient following a radical prostatectomy. The catheter includes an elongated member (11) having a drainage passage(12) extending longitudinally therein and a plurality of drainage ports (21) in a drainage portion (14) thereof for providing external access for the drainage passage in the bladder of the patient. First and second retention balloons (17, 18) are connected with the elongated member and positioned distally and proximally of the drainage ports, respectively. The elongated member also includes first and second inflation passages (26, 27) for individual and independent inflation and deflation of the retention balloons. One-way connector valves (32, 33) are positioned at the proximal end of the catheter for controlling inflation and deflation of the balloons via the inflation passages.Type: GrantFiled: February 4, 1998Date of Patent: October 9, 2001Assignee: Cook Urological, IncorporatedInventor: Neil H. Bander
-
Patent number: 6290956Abstract: The present invention is directed to the use of antibodies or binding portions thereof, probes, ligands, or other biological agents which either recognize an extracellular domain of prostate specific membrane antigen or bind to and are internalized with prostate specific membrane antigen. These biological agents can be labeled and used for detection of normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof. They also can be used alone or bound to a substance effective to ablate or kill such cells as a therapy for prostate cancer. Also disclosed are four hybridoma cell lines, each of which produces a monoclonal antibody recognizing extracellular domains of prostate specific membrane antigens of normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof.Type: GrantFiled: July 20, 1999Date of Patent: September 18, 2001Assignee: Cornell Research Foundation, Inc.Inventor: Neil H. Bander
-
Patent number: 6136311Abstract: The present invention is directed to the use of antibodies or binding portions thereof, probes, ligands, or other biological agents which either recognize an extracellular domain of prostate specific membrane antigen or bind to and are internalized with prostate specific membrane antigen. These biological agents can be labeled and used for detection of cancerous tissues, particularly cancerous tissues proximate to or containing vascular endothelial cells, which express an extracellular domain of prostate specific membrane antigen. The labeled biological agents can also be used to detect normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof. They also can be used alone or bound to a substance effective to ablate or kill such cells as a therapy for prostate or other cancers.Type: GrantFiled: July 17, 1997Date of Patent: October 24, 2000Assignee: Cornell Research Foundation, Inc.Inventor: Neil H. Bander
-
Patent number: 6107090Abstract: The present invention is directed to the use of antibodies or binding portions thereof, probes, ligands, or other biological agents which either recognize an extracellular domain of prostate specific membrane antigen or bind to and are internalized with prostate specific membrane antigen. These biological agents can be labeled and used for detection of normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof. They also can be used alone or bound to a substance effective to ablate or kill such cells as a therapy for prostate cancer. Also disclosed are four hybridoma cell lines, each of which produces a monoclonal antibody recognizing extracellular domains of prostate specific membrane antigens of normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof.Type: GrantFiled: April 9, 1997Date of Patent: August 22, 2000Assignee: Cornell Research Foundation, Inc.Inventor: Neil H. Bander